Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Vera Therapeutics announced positive topline results from its Phase 3 ORIGIN trial of atacicept for IgA nephropathy (IgAN), with participants showing a statistically significant 42% reduction in proteinuria compared to placebo (p<0.0001) at week 36. The safety profile was favorable, and Vera plans to meet with the FDA to discuss the results and intends to submit a Biologics License Application (BLA) for accelerated approval in Q4 2025, potentially leading to US approval and commercial launch in 2026. The ORIGIN 3 trial is ongoing, with two-year eGFR results expected in 2027.

Analysis

Vera Therapeutics (VERA) has announced compelling topline results from its pivotal ORIGIN Phase 3 trial for atacicept in treating Immunoglobulin A Nephropathy (IgAN), a significant development underscored by strongly positive sentiment (0.85 general, 0.9 for VERA) and a high market impact score (0.8). The trial met its primary endpoint, with atacicept achieving a statistically significant and clinically meaningful 42% reduction in proteinuria (UPCR) compared to placebo at 36 weeks (p<0.0001), alongside a 46% reduction from baseline. Notably, the company highlighted that ORIGIN 3 is the first Phase 3 trial in IgAN to demonstrate this magnitude of UPCR reduction versus placebo at this specific 36-week timepoint. The drug candidate, which has already received FDA Breakthrough Therapy Designation, also exhibited a favorable safety profile comparable to placebo. Based on these robust interim results, Vera Therapeutics intends to discuss these findings with the FDA and plans to submit a Biologics License Application (BLA) for accelerated approval in the fourth quarter of 2025, targeting a potential U.S. commercial launch in 2026. While these proteinuria findings are crucial for the accelerated pathway, the ORIGIN 3 trial is ongoing to assess long-term kidney function via estimated glomerular filtration rate (eGFR), with two-year data expected in 2027; current eGFR results are not being shared at this stage per FDA guidance due to the ongoing placebo-controlled nature of the trial.

Key Decisions for Investors

• The successful Phase 3 interim results for atacicept significantly de-risk Vera Therapeutics' lead asset and strengthen its near-term outlook, warranting a positive re-evaluation of the company's prospects given its potential as a first-in-class dual BAFF/APRIL inhibitor for IgAN.
• Investors should closely monitor Vera's upcoming discussions with the FDA, the planned Biologics License Application submission in Q4 2025 for accelerated approval, and subsequent updates on manufacturing and commercial launch preparedness for a potential 2026 market entry.
• While current proteinuria data strongly supports the accelerated approval pathway, the full eGFR results expected in 2027 will be critical for confirming long-term kidney function benefits and securing full approval, representing a key future catalyst and validation point to track.